Landmark legislation designed to disclose the manufacturing origins of generic drugs is moving toward a full Senate vote, but significant changes have been made to the bill since its introduction. The Clear Labels Act, originally introduced by Sens. Rick Scott, R-Fla., and Kirsten Gillibrand, D-N.Y., has been stripped of two provisions safety experts identified as critical to its effectiveness: the requirement for a unique facility identification code on drug labels and the initial one-year timeline for compliance.
The bill seeks to mandate that drug labels disclose where medications were manufactured, rather than just the location of the packager or distributor. This push for transparency follows a ProPublica investigation which found that the U.S. continued importing generic drugs from foreign factories even after inspectors identified quality and safety lapses, including mold, leaks, and contaminated water. Medications produced at these facilities were linked to thousands of reported adverse reactions in patients.
What the Left Is Saying
Progressive advocates and health policy experts argue that the changes significantly weaken the bill's ability to protect consumers. Dr. Kevin Schulman, a professor of medicine and health policy at Stanford University, stated that the extended timeline is excessive, noting, "Five years after it passes might as well be a lifetime." He questioned the reluctance of the supply chain to ensure high-quality products.
Critics point out that removing the unique facility identifier, known as a DUNS number, makes it difficult for researchers and the public to track the regulatory histories of specific manufacturing sites. ProPublica reporters previously used these identifiers to connect 69% of prescription drug labels to specific facilities, a level of traceability that advocates say is lost when only physical addresses are required.
What the Right Is Saying
Sen. Rick Scott and Sen. Kirsten Gillibrand described the bill's progress in the Senate as a "massive win for consumer safety and transparency" in a joint press release, though they did not explicitly address the removal of the unique identifier provision. A representative from Gillibrand’s office explained that the five-year delay is intended to provide the Food and Drug Administration (FDA) sufficient time for rulemaking, which is often a lengthy process.
According to the representative, the extended timeline also allows manufacturers time to come into compliance and redesign their labels. Lawmakers who supported the changes expressed concerns that the original strict requirements could raise drug prices and potentially weaken national security by revealing the precise locations where lifesaving medications are produced.
What the Numbers Show
The original version of the Clear Labels Act required compliance within one year of passage. The amended version extends this period to five years. The bill no longer mandates the inclusion of a DUNS number, which is the FDA's unique identifier for factories. Instead, labels will only be required to include factory addresses.
Data from ProPublica’s Rx Inspector tool indicates that addresses alone are often insufficient for traceability. In cases where only an address was available, linking a drug to a particular facility required a complex automated process. A single address in countries like India can house multiple factories, each producing different drugs or variations of the same drug, making it difficult to pinpoint the specific manufacturing site responsible for a medication.
Peter Baker, a former FDA inspector, noted that the five-year period is unnecessary for such a change. "If they wanted to do it in one year, they could," Baker said. "I would love to hear their justification on why they need five years to develop some rules and guidance on transparency. … I mean, it’s a simple label change."
The Bottom Line
The Senate is preparing for a final vote on the amended Clear Labels Act, which retains the core mandate for disclosing manufacturing locations but sacrifices the precision and speed of the original proposal. Supporters argue the changes are pragmatic accommodations for industry and regulatory constraints, while critics contend the removal of the unique identifier and the extended deadline dilute the bill's power to hold manufacturers accountable for safety lapses.
If passed, the law will require generic drug labels to display factory addresses, but consumers and researchers may still face challenges in tracing medications back to specific facilities without the unique DUNS code. The debate highlights the ongoing tension between consumer transparency, national security concerns, and the logistical realities of global pharmaceutical supply chains.